Axitinib (AG-013736).

@article{Kelly2010Axitinib,
  title={Axitinib (AG-013736).},
  author={Ronan Joseph Kelly and Olivier Rixe},
  journal={Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer},
  year={2010},
  volume={184},
  pages={
          33-44
        }
}
The vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK) signaling pathway plays a pivotal role in tumor angiogenesis. Neovascularization promotes increased tumor cell proliferation, survival and metasasis. Many antiangiogenic agents including multi-RTK inhibitors are either approved or are undergoing testing in clinical trials. Axitinib is a potent and selective inhibitor of VEGF RTK 1, 2, and 3. This chapter discusses the stucture of axitinib as well as its toxicities… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Combined VEGF/PDGF inhibition using axitinib induces αSMA expression and a pro-fibrotic phenotype in human pericytes

  • Graefe's Archive for Clinical and Experimental Ophthalmology
  • 2018
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Metastatic melanoma – a review of current and future drugs

  • Drugs in context
  • 2012
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED